Gloria Marquina

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Socioeconomic disparities in sarcoma diagnosis, expert center access, and advocacy group awareness: a multicenter study in Southern Europe.

Socioeconomic disparities in sarcoma diagnosis, expert center access, and advocacy group awareness: a multicenter study in Southern Europe.

Journal: The oncologist

Published: July 23, 2026

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Journal: JAMA oncology

Published: June 25, 2026

Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort.

Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort.

Journal: The oncologist

Published: February 27, 2026

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

Journal: The oncologist

Published: February 27, 2026

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.

Journal: JAMA oncology

Published: February 26, 2026

Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium.

Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 10, 2026

International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease.

International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease.

Journal: ESMO open

Published: October 29, 2025

Bevacizumab-Associated Renal Adverse Events Signal Better Prognosis in Ovarian Cancer: A Double-Edged Vascular Endothelial Growth Factor Inhibition.

Bevacizumab-Associated Renal Adverse Events Signal Better Prognosis in Ovarian Cancer: A Double-Edged Vascular Endothelial Growth Factor Inhibition.

Journal: Kidney360

Published: October 09, 2025

How Should Primary Pulmonary Sarcoma be Staged? Results of an International Multicentre Analysis.

How Should Primary Pulmonary Sarcoma be Staged? Results of an International Multicentre Analysis.

Journal: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

Published: September 04, 2025

Chemotherapy and Other Systemic Drugs Used to Treat Gynecologic Carcinosarcomas (GCSs): A Retrospective Analysis from Hospital Clínico San Carlos (HCSC), An Academic Referral Centre for Rare Gynecological Malignancies in Madrid, Spain.

Chemotherapy and Other Systemic Drugs Used to Treat Gynecologic Carcinosarcomas (GCSs): A Retrospective Analysis from Hospital Clínico San Carlos (HCSC), An Academic Referral Centre for Rare Gynecological Malignancies in Madrid, Spain.

Journal: Cancers

Published: September 02, 2025

Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines.

Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines.

Journal: Cancers

Published: August 19, 2025

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Journal: Nature communications

Published: August 18, 2025

Showing 1-12 of 52

Last Updated: 09/26/2026